Trial will evaluate a once-daily dose of raltegravir.
D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000627:therapeutic use; D018791:CD4 Lymphocyte Count; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use; D004311:Double-Blind Method; D004338:Drug Combinations; D004359:Drug Therapy, Combination; D000069480:Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; D015658:HIV Infections / Q000188:drug therapy*; D019428:HIV Integrase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D015337:Multicenter Studies as Topic; D009943:Organophosphorus Compounds / Q000008:administration & dosage / Q000627:therapeutic use; D011760:Pyrrolidinones / Q000008:administration & dosage / Q000627:therapeutic use; D012367:RNA, Viral / Q000097:blood; D000068898:Raltegravir Potassium; D016032:Randomized Controlled Trials as Topic
D019380:Anti-HIV Agents; D004338:Drug Combinations; D000069480:Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; D019428:HIV Integrase Inhibitors; D009943:Organophosphorus Compounds; D011760:Pyrrolidinones; D012367:RNA, Viral; D003841:Deoxycytidine; D000068898:Raltegravir Potassium